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Venturing into venture philanthropy: Is more sustainable health and medical research 
funding possible through venture philanthropy and social entrepreneurship?  
Dr Wendy Scaife, Australian Centre of Philanthropy and Nonprofit Studies,  
Queensland University of Technology 
 
Abstract 
Resource issues of Australia’s aging population are wrinkling the strategists’ brows.  A quest 
for novel funding options is underway.  This paper draws upon case study research to raise 
the allied concepts of venture philanthropy and social entrepreneurship as useful partners in a 
nation’s medical research funding portfolio.  While both notions are quite new features in the 
nonprofit and philanthropy literatures (Van Slyke and Newman 2006) US cases suggest a 
tangible benefit to the health system that is worth exploring for Australia.  This replicability 
potential is considered, along with its implications for medical research, philanthropic and 
government leaders.  This paper is an early investigation of these concepts in the health and 
medical research setting.  
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Venturing into venture philanthropy (VP): Is more sustainable health and medical 
research funding possible through venture philanthropy and social entrepreneurship?  
Introduction 
Governments and futurists across the globe are grappling with the spiralling costs of funding 
the health needs of greying nations.  In Australia, for instance, the national health bill is 
forecast to more than quadruple by 2050.   Philanthropy has been raised in various forums as 
an income source that could be a more robust resource in the health funding mix, particularly 
for health and medical research, which may through prevention keep health costs down.  This 
paper draws upon a recent examination of creative international examples of health and 
medical research philanthropy and specifically considers two cases of venture philanthropy 
(VP) tailored by social entrepreneurs to achieve outcomes in this sector.  VP has entered the 
spotlight at a time when as Frumkin suggests, there are ‘rising doubts about the impact of 
philanthropy’s diverse and diluted efforts’ especially in fields where ‘the need for broad 
system-wide change has forced donors to look for ways to increase the impact of their giving’ 
(2002, 7).  Many believe VP can achieve the ‘seven-league boot strides’ needed in social 
challenges.  As Fleishman suggests, ‘it is becoming obvious that venture philanthropy and 
social entrepreneurship have significantly greater impact than dollars spent the old-fashioned 
way’ (2007, 126). 
This paper briefly scans the literature of VP and social entrepreneurship (SE) then two case 
studies are profiled, prior to some discussion.  It concludes that with appropriate policy 
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support and promotion, Australia could benefit from a similar ‘venturing’ towards venture 
philanthropy.   
Literature backdrop 
Medical research as a cause.  The philanthropic dollar has long been attracted to medical 
research and it appears a popular destination for donated dollars in many countries.  For 
instance in Australia, health/medical research nonprofits attract one in seven of all individual 
donation dollars, and nearly one in five dollars donated by business (Giving Australia 2005).  
In the UK, medical research attracts more supporters than any other cause and is supported by 
40% of donors (McCaffrey 2007). Approximately a third of all public expenditure on health 
and medical research in the UK comes from medical research charities (Association of 
Medical Research Charities 2007).  In 2006, 17% of all donations went to medical research, 
ahead of religion at 16% (Charities Aid Foundation 2007).  A comprehensive 2000 survey 
showed Canadian voluntary health organizations received 20% of the total value of all 
donations (Canadian Center for Philanthropy 2000).  However, non-Western nations may 
differ.  For instance in Korea, in 2002 only 2.9% of individual giving went to health and 
medical organisations (Park and Park 2004).   
 
Some of the largest research bodies in the world owe their existence to philanthropy, such as 
the UK’s Wellcome Trust, the US Howard Hughes Medical Research Institute or Australia’s 
Walter and Eliza Hall Institute.  In fact, in the US, philanthropy, not government played the 
central role in funding medical research and these inputs have cast a long shadow of impact.  
For instance, in 1910 the Carnegie Foundation funded a study on the state of medical 
education that saw a complete revamp of the nation’s medical delivery and the Rockefeller 
Foundation established the first clinical research hospital, school of public health and the 
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Population Council (Field, Plager, Baranowski, Healy and Longacre (2003).   However, 
documented barriers suggest medical research is not a preferred option for some 
philanthropists for a variety of reasons.  A belief that financing medical research is totally the 
government’s responsibility, that research is plagued by duplication, that philanthropic input 
is too small to make a difference, that good science is too hard to judge and that any ‘return’ 
on investment is too longterm and uncertain are commonly cited obstacles to philanthropic 
funding of medical research (Centre of Philanthropy and Nonprofit Studies 2005).  In similar 
vein, small and large trusts and foundations report being most comfortable with research that 
can demonstrate outcomes.  ‘Philanthropies… want to support research that can make a 
positive impact on people’s lives… and see that research get implemented day-to-day’ 
(Donaghue Foundation, 1111).   
 
The VP concept offers perhaps a stronger chance of this outcome, as the next section outlines.  
That the idea has taken root at least in the US is evident in examples such as the cases 
presented in this article and also in the tenfold growth in investment in the biopharmaceutical 
industry by US disease foundations since 2000 reported by Gambrill (2007).   Five 
foundations with a venture philanthropy component are the Cystic Fibrosis Foundation, 
Multiple Myeloma Research Foundation, Muscular Dystrophy Association, Juvenile Diabetes 
Research Foundation and the Michael J. Fox Foundation for Parkinson’s Research.  She 
attributes this uptake of VP by the medical research sector to several factors: 
• A reduced National Institutes of Health budget,  
• Concern that academic research has little incentive to translate into the clinic, and 
• The financial inability of biotechnology companies to fund in preclinical stage of drug 
development particularly in rare diseases. 
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Venture philanthropy.  The limited academic literature and more bountiful practitioner 
documentation highlight several themes about VP.  While still without a clear definition (Van 
Slyke and Newman 2006, 346; Morino 1997), consistent threads span writings on the notion, 
that some now refer to as ‘Philanthropy 2.0’ (Foote 2007) , ‘performance philanthropy’ 
(Fahmy 2004), ‘philanthropy with attitude’ (Hesselein 2001), ‘philanthropy reinvented’ and 
‘the next wave of philanthropy’ (Lee 2006), or ‘social venture philanthropy,’ ‘the new 
philanthropy’, and ‘social venturing’ (Kirsch Foundation 2007).  These themes include: 
• An entrepreneurial investor giving significant resources plus usually strategic or 
technical assistance (see for instance Van Slyke and Newman 2006 analysis of VP and 
SE in community redevelopment).  As Fahmy suggests, the result is ‘businesslike 
charities that pursue social returns as aggressively as their firms do profits’ because 
‘high engagement grant makers follow the principles of venture capitalism by 
supplementing their financial support with managerial assistance’ (2004:1).  Venture 
philanthropy is described as much more ‘management intensive’ as a result; 
• Adaptation of venture capital principles (see Letts, Ryan and Grossman’s seminal 
1997 article for the genesis of this thinking).  Fahmy’s 2004 description of Social 
Venture Partners also underlines the importance of the due diligence angles to assess 
the risk and growth potential of ideas to be backed.  Frumkin (2003) also points out 
that the technology boom of the 1990s itself breathed fresh life into the old concept of 
venture capital so it is logical that VP investors schooled in these methods have honed 
in on traditional venture capital issues such as undercapitalisation as they seek to turn 
donations into hard-nosed social investments; 
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• A high level of engagement between the philanthropist and their fundee compared 
with what is characterised colloquially as ‘armchair philanthropy’ or ‘chequebook 
giving’.  (Morino 2004 in fact delineates VP as ‘high engagement philanthropy’.)  
Frumkin (2003, 11) highlights this consultative engagement as a key reengineering of 
the mainstream philanthropy model, saying VP has focused on changing the funder- 
recipient relationship.  Instead of sinking effort into selecting grant recipients alone, 
VP ‘extends the time horizon and deepens the contact between all parties’ (11).  Given 
the move in the fundraising literature toward more donor-based approaches (see for 
example Sargeant and the longterm view that fundraising hinges on building 
relationships and commitment, VP captures the essence of what the field has 
anecdotally felt to be important.  Frumkin (12) also points to the desire for many 
wealthy people to find meaning in their lives outside of business, particularly those 
who have made large amounts of money at a young age, such as the technology 
entrepreneurs.  This underlines the literature on high net worth giving such as (); 
• Willingness to fund longer term, compared with the common one to three year grants 
typical in the past (As Fahmy (2004) suggests if the business model shows promise, 
the venture philanthropy fund stays involved for several years.)  This often sees 
venture philanthropists focus on a smaller number of projects to traditional 
foundations.;Intent to build capacity within the funded organisation (see Letts and 
Ryan’s analysis of high engagement philanthropy not only as capacity building but 
also as an accountability relationship where funders help nonprofits improve their 
performance but also hold them accountable for it); 
• A wish to fund at the ‘lowest rungs of the socioeconomic ladder’ (Lee 2006) or those 
otherwise in real need (e.g. those facing life-threatening or chronic diseases) 
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• A desire to operate on a different model to traditional philanthropy (see Hafner 2006 
for a description of how Google’s philanthropic arm, Google.org has set up as a for 
profit, to allow it to fund start-up companies, partner with venture capitalists and even 
lobby governments.  ‘the traditional structure of corporate foundations [is like] a 
musician confined to playing only the high register on a piano.  “Google.org can play 
with the entire keyboard…it can start companies, build industries, pay consultants, 
lobby, give money to individuals and make a profit [to be reinvested in Google.org]. 
Making the way results are assessed a centrepiece of their work to overcome the lack of 
benchmarks that have concerned some donors in the past and to guide better ‘investment’ 
decisions in the future.  (According to Frumkin, ‘giving seemed condemned to an emotive 
exercise that never asked tough questions’ (2002, 13).  this has led to the advent of reports 
such as the Roberts Enterprise Development Fund’s Social Return on Investment Reports that 
measure the ‘enterprise value’ (financial return for the business) and ‘social purpose value’ 
(the monetised public cost savings and taxes generated by the enterprise employees) (see 
Frumkin 2003, 13).  In reality Frumkin suggests the move is little more than a cost-benefit 
analysis using underlying evaluation methods from the 1960s but the rhetoric has captured the 
attention of donors.  He points out (14) that no simple monetary measures have yet been 
developed for many nonprofit ventures including advocacy, orchestra performances, faith-
based counselling aimed at promoting family unity and so on.  In addition, it is impossible in 
reality to isolate programs from the other social and economic forces affecting 
outcomes.Frumkin goes on to portray VP as a three legged stool, ‘each leg of which is seen as 
a solution to a problem in traditional philanthropy that has impeded nonprofit organizations’ 
(2003, 9).  The three legs are capitalization, engagement and performance management: large 
blocks of capital delivered over an extended period to build np capacity; improving np 
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strategy through management consulting and developing new metrics.  Nonprofits have 
welcomed the new form of giving in light of the move by many funding sources to support 
projects not organisations and to regard basic operational and infrastructure expenses as ‘non-
essential’.   
He does however challenge (15) that VP is not really appealing new names for old concepts, 
as his Venture Philanthropy Terminology Table suggests.  He says an investment portfolio in 
VP terms is just a grant list, due diligence is akin to grant review, social return is impact and 
so on.  He suggests it will take important practice breakthroughs to ‘make good on the new 
language’ (15) and take VP from a position of ‘unfulfilled promise’ though undeniable 
‘marketing triumph’. 
The concept can be found written up across various cause areas – ‘be it economic 
development of the inner city, access to health care, reduction in youth violence, or reform of 
public schools’ (Frumkin 2003, 7).  Evidence suggests many VPs focus on areas of reform 
where isolated small projects are unlikely to bring the scale of change needed for major 
systemic change (Frumkin uses the example of John Doerr’s New Schools Venture Fund to 
illustrate this angle – see p10-11).  Renfro (2005) for instance reports on the injection of 
philanthropic venture capital through the Duke Endowment to rural economic development in 
the two Carolinas in the southeast of the US.  The cycle of development they are engaged 
upon by using venture philanthropy is included as  Figure 1. 
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Figure 1 The Cycle of Development adapted from Renfro 2006.Fahmy outlines groups such 
as the Acumen Fund which channels money from wealthy donors to projects in Asia and 
Africa, Geneva Global which advises donors on specific projects and MicroVest, which offers 
a financial return on investments made into microlending in developing countries.  Acumen 
and Geneva Global channel funding into health care and economic development efforts 
globally.  Social Venture Partners (as described by Fahmy 2004) is one of an estimated 50 
venture philanthropy organisations in the US, up from ten in 1997.   
A capable and 
productive workforce, 
safe appealing 
environment, good 
public health, good 
community amenities 
Good jobs that permit 
people and 
communities to earn 
income and build 
assets. 
Public and private 
investment in schools, 
government, 
development and 
community 
organisations, human 
and social services 
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The genesis of the VP concept is said to lie in the 1980s when US banking and technology 
entrepreneurs led by hedge fund manager Paul Tudor Jones II founded New York’s Robin 
Hood Foundation in a spate of initiatives that saw those who had profited from the technology 
boom start to put a new stamp on philanthropy.  Yet, as Fahmy points out, the dollars invested 
in venture philanthropy are negligible compared with overall charitable giving. 
Some posit that the growth of VP is linked in some ways to concerns with traditional 
philanthropy.  Fahmy for instance cites concerns about npo  mismanagement and fraud that 
abounded post September 11 and other crises. 
Veteran academic Katz (2005) describes VP as ‘the hottest trend in philanthropy’ and some 
42 foundations identified themselves as venture philanthropists in 2004 (Said 2005).  
However, some suggest the trend is more about rhetoric than a philanthropic ‘sea change’ or 
as Kramer posits, ‘more evolution than revolution’.  To more objectively consider the impact, 
a call has been made for substantive investigation of the concept through primary data 
sources, such as case studies and other empirical modes (Van Slyke and Newman 2006, 347). 
By way of summary, the National Venture Capital Association characterises VP as focusing 
on ‘leadership, bold ideas, developing strong teams, active board involvement, and long-term 
investment’ (http://www.nvca.org/philanthropy.html).  This organisation has also formed 
an Entrepreneurs Foundation to engage high growth companies in corporate citizenship and 
philanthropy.  Participating companies donate a contribution of their pre-IPO stock.  The link 
between VP and SE appears strong.  As the following section suggests, perhaps VP could be 
regarded as one stream amongst many fresh philanthropic ideas and business models that 
social entrepreneurs are bringing to the field.   
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Google.org, the search engine’s charitable foundation sums up the philosophy that prompted 
new philanthropic models in expressing that it was looking for the most efficient and effective 
ways to solve the world’s largest problems (Lee 2006). 
Social entrepreneurshi  Again, academic literature on this topic is scant (Dorado 2006, 321) 
and agreement on the meaning of the term yet to be achieved.  Research has been an 
outgrowth of earlier general work on entrepreneurship, however, Dorado (2006) cautions that 
research on entrepreneurial ventures does not necessarily translate to the field of social 
entrepreneurial ventures.  Research in this differentiating vein also includes work on traits 
(see for example Dees’ five differentiating facets of social entrepreneurs compared with for 
profit entrepreneurs).  In particular, Alvord Brown and Letts (2003, 145) have highlighted the 
ability of the social entrepreneur to be a bridge, and able to ‘work effectively across many 
different constituencies’.  Some work has been in the form of case studies, such as Van Slyke 
and Newman’s 2006 study of entrepreneur Tom Cousins who sought an organisation that 
could enact his vision to redevelop the Eastlake community.  When one was not in evidence, 
Cousins created such an operation himself, just as in the past he had created new businesses 
for profit, emphasising the concept of overcoming institutional and environmental limitations 
(365). 
The advent of VP and SE come at a time when ‘new philanthropy’ is being urged to ‘expand 
beyond its traditional funding capacity’ (Donaghue Foundation, 1111).  Some fresh directions 
seem more promising than others in the arena of health and medical research.  For instance, a 
new US philanthropic organisation, Prize4Life recently announced a million dollar award for 
any scientist able to find a biomarker for Lou Gehrig’s disease.  In response, researchers have 
noted the need to have money to do the research, not achieve it afterwards (Waltz 2006, 
1334).  Other novel philanthropic approaches toward funding medical research reported by 
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Waltz include the monetary incentive businessman Scott Johnson has applied through his 
Myelin Repair Foundation to top university MS researchers to merge their laboratories and 
adopt a more businesslike approach to developing treatments.  A similar effort is underway in 
Multiple Myeloma where patient and pharmaceutical executive Kathy Giusti has used US$60 
million in funds raised to achieve more research synergies.  For instance, she has encouraged 
four leading cancer centres to coordinate their clinical trials and share their findings and 
resources.  Another female philanthropist, pioneering geneticist and Nobel Prize winner 
Christiane Nusslein-Volhard has used her own money to set up a foundation that funds 
childcare arrangements for female researchers.  Philanthropy in medical research has also 
featured recently in the form of the stopgap multimillion dollar infusion to California’s stem 
cell research program to keep it afloat whilst lawsuits challenging its constitutionality play out 
(Pollack 2006). 
However innovative these diverse applications of philanthropy to medical research, and 
however sizeable the input of preceding generations of philanthropists, the literature and 
commentary point to VP and SE as the more promising strategies to create targeted change. 
As Fleishman suggests, ‘it is becoming obvious that venture philanthropy and social 
entrepreneurship have significantly greater impact than dollars spent the old-fashioned way’.  
How have these operated in practice? 
Case studies of VP and SE in medical research 
Using a literature scan, web searches, and in-depth personal and telephone interviews, the 
Centre of Philanthropy and Nonprofit Studies sought to locate case samples of creative 
practice in health and medical research philanthropy.  Two examples of VP operationalised by 
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social entrepreneurs emerged and are profiled here – Goldman Philanthropic Partnerships and 
the Institute for the Study of Aging. 
Goldman Philanthropic Partnerships (GPP). Founded by former merchant bank 
founder and entrepreneur George N. Goldman and his multiple myeloma patient wife, Judith 
in 1998, GPP was set up to change and accelerate the way cures are discovered.  It creates 
innovative research funding partnerships (called ‘Inspired Ventures) between donors, 
researchers and renowned research institutions.  Donors select from a portfolio of projects 
sought from household name institutes (Mayo, Harvard etc) and give to a specific research 
project in their area of interest.  GPP instigates and manages the entire process, allaying donor 
fears about the donation reaching the mission.  It oversees program budgets and leverages 
every donation at least dollar for dollar from the host research institution itself or another 
source.  Each project is validated by GPP’s science advisers and progress is reported to 
donors every 90 days.  Opportunities for personal involvement are fostered and research 
institutes are encouraged to offer cutting-edge research that may not attract more mainstream 
funding.  An interesting facet of this approach is that GPP is changing not only medical 
outcomes but also society’s views and behaviour in funding medical research.  People who 
may not have engaged in giving let along giving for medical research funding are accessed 
through the organisation’s networks.  GPP is creating a society more attuned to and 
comfortable with the need to inject community funds to leverage more traditional funding 
sources. 
GPP has now also created an offshoot public charity, Partnership for Cures, with a Two Years 
to Cures program that gathers donations to repurpose already approved safe and effective 
drugs so they can be potentially applied to other likely disease areas.  Given that the average 
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time for a medical breakthrough to become part of widely accepted clinical practice is 17 
years, this entrepreneurial stroke is dramatic (The Donaghue Foundation 2007, 1111).   
The Institute for the Study of Aging (ISOA). With a limited budget of some millions a year to 
disburse, the Estee Lauder Trust felt it could leverage its input to medical research better with 
a new model.  Coining the phrase, biomedical venture philanthropy, ISOA was created to fill 
the gap between traditional funding of basic research into Alzheimer’s disease by government 
and the later stage clinical development funded by venture capitalists and pharmaceutical 
companies.  Operating akin to a venture capital firm, ISOA identifies high potential ideas in 
drug discovery, supports these with financial, technical and strategic management help, 
establishes networks and collaborations and monitors outcomes.  It funds projects to proof of 
principle stage when other investors will pick them up, knowing ISOA has validated the 
science.  ISOA also funds start-up and biotechnology companies using either program 
investments or recoverable grants.  The philosophy is that philanthropists can and should take 
some of the risks that other funders find it harder to do.  More than 100 programs have been 
funded worldwide.  A public charity, the Alzheimers Drug Development Foundation has been 
created to operate alongside the Lauder family’s private trust to increase the span of the 
program. 
The Acumen Fund and A-Z Textile Mills. Because more than a million Tanzanians die 
annually from malaria, health prevention mecahanisms are imperative.  Five years ago, the 
small family owned A-Z Textile Mills in Tanzania making mosquito nets wanted to expand to 
provide more nets.  With an investment from the nonprofit charity Acumen Fund it today 
employs 2,000 people and has sold more than five million nets, with production now 
escalating to seven million a year.  In an innovation, the nets carry long lasting insecticide.  A 
more traditional form of philanthropy probably would not have gone to a commercial 
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enterprise already geared to this market.  Acumen is a  philanthropic venture capital fund that 
employs people with business acumen.  It invests in companies and groups that tackle global 
poverty and the issues that such poverty brings (Lee 2006).  Evaluations of projects are made 
on the basis of social impact, financial sustainability, replicability and breakthrough insights 
that can be used elsewhere.  It raises charitable money but then applies it with the flexibility 
of grants, loans and equity investments in for-profit and non-profit organisations alike.  The 
loan arrangement has seen Acumen able to reap a return of $422,500 from its original 
$325,000 loan to A-Z to build its factory.  Acumen costs the management of the loan project 
at $130,000 across the five years, meaning that it has achieved 2,000 ongoing jobs in a poor 
economy as  well as safeguarding millions now and in the future against malaria for a net loss 
of $32,500 (Hempel 2007). 
Discussion 
‘You can’t take business practices and superimpose them when it comes to social issues’ 
according to Professor Allen S. Grossman who studies entrepreneurship in the social sector 
(in  Lee 2006).  He calls for ‘social adaptations so that there is not a conflict between good 
business practices and achievement of a social mission’. 
Both the Goldmans and the Lauders represent social entrepreneurs who have embraced 
venture philanthropy.  Akin to the Cousins example cited by Van Slyke and Newman (2005) 
in the literature section, they have each created their own model strategically and set about 
operationalising it.  The themes of VP and SE are richly evident in both cases – 
entrepreneurial tailoring to the needs of stakeholders, innovative approaches to longstanding 
issues, leverage, partnerships, significant input beyond mere dollars, building a bridge 
between different constituencies and a commitment to engage longterm.  Their leadership of 
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the respective organisations is both transformational and trust-engendering.  Arguably, despite 
the documented differences between US philanthropy and that of other nations, both models 
could feasibly be replicated in other countries such as Australia.  Both the taxation incentives 
and the culture of giving may differ in the US but nothing in the cases would be unacceptable 
in an Australian nonprofit context.  Given that Australia’s National Health and Medical 
Research Council has just appointed someone to lead its new strategic area of philanthropic 
funding, it is possible that assistance would be given to trial the concept locally. 
The adaptation of an existing foundation to operate under a VP model as in the ISOA case 
offers a template for interested foundations to emulate and build on.  Currently in Australia 
there is no health and medical research affinity group within the main body that operates for 
philanthropists, Philanthropy Australia.  However, science advocacy group, Research 
Australia has just achieved government and philanthropic funding of a Centre for Health and 
Medical Research Philanthropy which may take such concepts to traditional foundations.   
The use of an allied public charity in both cases has clearly multiplied the impact of the effort 
and embraced a new range of supporters.  Given the existing numbers of health and medical 
research charities and their popularity with the giving public, opportunities for linkages rather 
than setting up fresh charities may be the preferred option for Australia. 
The key implication for policymakers, philanthropic and medical research leaders in Australia 
is that tangible returns are flowing from a paradigm that business people trust and have an 
inherent familiarity with from their for-profit investments.  In the absence of a Lauder or 
Goldman entrepreneur in Australia, it may be possible to showcase and promote the model to 
potentially interested groups to highlight the venture philanthropy concept.  Visits from the 
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now growing number of health and medical research venture philanthropists in the US may 
hasten this process. 
These cases are exploratory and potential further steps may involve research with Australian 
philanthropic sources to investigate their comfort with a move to a different granting model.  
Policymakers may wish to target particular disease areas of need and opportunity and 
leverage government funding as an incentive to new entrants from philanthropy seeking to 
maximise their impact. 
Conclusion 
The fiscal health of medical research is intimately linked to the health of a nation.  New 
models such as the ‘signature’ entrepreneurial funding evident in the two cases, may offer 
some answers to the puzzle of how to find new funding sources for the health of aging 
nations.  
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